{
    "Trade/Device Name(s)": [
        "Human IgM Kit for use on SPAPlus",
        "Human IgM kit for use on SPAPLUS\u00ae"
    ],
    "Submitter Information": "The Binding Site Group Ltd.",
    "510(k) Number": "K191465",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082129"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFN"
    ],
    "Summary Letter Date": "May 28, 2019",
    "Summary Letter Received Date": "June 3, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgM"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Binding Site SPAPlus analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetry",
        "Turbidimetric assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for the Human IgM Kit for use on SPAPlus, a turbidimetric immunology assay for quantitation of IgM in serum or plasma.",
    "Indications for Use Summary": "Quantitative in vitro determination of human IgM in serum, lithium heparin or EDTA plasma using the Binding Site SPAPlus analyser to aid in diagnosing abnormal protein metabolism and immune deficiency, interpreted alongside clinical findings.",
    "fda_folder": "Immunology"
}